Climb Bio (CLYM) Akcie Kurz

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wilmington, Delaware and currently employs 30 full-time employees. The company went IPO on 2021-08-10. The company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver improved therapeutics for patients with these disorders. Its lead program is ETX-123, a Kv7.2/3 potassium channel opener. Kv7.2/3 has been clinically validated as a therapeutic target for both epilepsy and pain, with further encouraging clinical data in depression. Its ETX-123 lead candidate is an generate new chemical entities designed to harness the efficacy of the Kv7.2/3 channel mechanism while attempting to improve the safety and tolerability relative to earlier molecules, based on its insights into the mechanisms of toxicity and the potency and selectivity profile.